People · Operator
Named in public records as an officer, director or promoter · active 2012–2019 · Pharmaceuticals, Biotechnology, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pernix Therapeutics Holdings, Inc. | — | Pharmaceuticals | Series B | $34.0M | $1.2B | 2012 |
| Geom Therapeutics, Inc. | — | Biotechnology | Series A | $4.4M | $157.4M | 2017 |
| Dominion Aesthetic Technologies, Inc. | — | Software / Tech | Seed | $2.0M | $6.4M | 2017 |
COOPER COLLINS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside COOPER COLLINS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Smith | 1 | 20 |
| David Becker | 1 | 7 |
| Dov Goldstein | 1 | 6 |
| Dennis Condon | 1 | 5 |
| Steven Elms | 1 | 5 |
| Janet Campbell | 1 | 3 |
| Dirk Thye | 1 | 3 |
| GERARD SHERIDAN | 1 | 2 |
| Anthem Blanchard | 1 | 2 |
| Yong-Zu Kim | 1 | 1 |
| Sejin Park | 1 | 1 |
| Michael Pearce | 1 | 1 |
| Tracy Clifford | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.